<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00408148</url>
  </required_header>
  <id_info>
    <org_study_id>RIMON_C_01346</org_study_id>
    <secondary_id>EUDRACT # : 2006-001716-71</secondary_id>
    <nct_id>NCT00408148</nct_id>
  </id_info>
  <brief_title>High Density Lipoprotein Turnover</brief_title>
  <official_title>A Randomized, Double-blind, Two Arm, Parallel, Placebo Controlled Study of Rimonabant 20 mg Effect on High Density Lipoprotein Kinetics in Patients With Abdominal Obesity and Additional Cardiometabolic Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the effect of Rimonabant 20mg in comparison to&#xD;
      placebo, on HDL and VLDL lipoprotein kinetics, over a 12 months period.&#xD;
&#xD;
      Primary objectives:&#xD;
&#xD;
        -  To assess effect of Rimonabant on HDL ApoA-I fractional catabolic rate (FCR).&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To assess effect of Rimonabant on HDL ApoA-I production rate (PR) and on other&#xD;
           lipoprotein kinetics.&#xD;
&#xD;
        -  To assess effect of Rimonabant on lipids, glycemic and inflammatory parameters&#xD;
&#xD;
        -  To assess effect of Rimonabant on body composition&#xD;
&#xD;
        -  To assess safety of Rimonabant&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decision has been taken in light of recent demands by certain national health&#xD;
    authorities&#xD;
  </why_stopped>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The fractional catabolic rate (FCR) of HDL ApoA-I</measure>
    <time_frame>After 12 months of treatment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Production Rate (PR) of HDL ApoA-I and A-II, (FCR) of HDL ApoA-II</measure>
    <time_frame>All across the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PR and FCR of VLDL1 and VLDL2 Apo B, VLDL1 and VLDL2 TG, IDL Apo B and LDL Apo B</measure>
    <time_frame>All across the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in ApoA-I, ApoA-II, Lp-AI, Lp-AII, pre-beta-HDL HDL2a, HDL2b, HDL3a, HDL3b, HDL3c, Apo B, Apo C III, TG, LDL-C, HDL-C levels</measure>
    <time_frame>All across the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in Glucose, insulin, HbA1c, leptin, adiponectin</measure>
    <time_frame>All across the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in hs-CRP, TNF-alpha, CETP, PLTP and LCAT activities, lipoprotein and hepatic lipase activities in post-heparin plasma</measure>
    <time_frame>All across the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in whole body fat</measure>
    <time_frame>All across the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in abdominal sub-cutaneous and visceral fat</measure>
    <time_frame>All across the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in liver fat</measure>
    <time_frame>All across the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in blood pressure</measure>
    <time_frame>All across the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in body weight, waist circumference, waist/hip ratio</measure>
    <time_frame>From the beginning to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CE/TG ratio in HDL</measure>
    <time_frame>All across the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From the beginning to the end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of one rimonabant placebo tablet once daily in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of one tablet containing 20 mg of active rimonabant once daily in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Undistinguishable placebo tablets</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimonabant</intervention_name>
    <description>White film-coated, for oral administration containing 20 mg of active rimonabant</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Abdominally obese patients with additional cardiometabolic risk factors&#xD;
&#xD;
          -  Females must be post-menopausal&#xD;
&#xD;
          -  BMI &gt; 27 kg/m² and &lt; 40 kg/m²&#xD;
&#xD;
          -  Men or women with abdominal obesity according to NCEP/ATPIII criteria: Waist&#xD;
             Circumference &gt; 88 cm in women; &gt; 102 cm in men&#xD;
&#xD;
          -  With at least one lipid abnormality defined as:&#xD;
&#xD;
          -  Fasting Triglycerides level &gt; 1.7 mmol/L (150 mg/dL) and &lt; 4.5 mmol/L (400 mg/dL)&#xD;
&#xD;
          -  HDL &lt; 1.03 mmol/L (40 mg/dL) in men and &lt; 1.29 mmol/L (50 mg/dL) in women&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HDL ≤ 0.60 mmol/L (23 mg/dl)&#xD;
&#xD;
          -  Plasma LDL-Cholesterol &gt; 155 mg/dl (4.00 mmol/L) or total cholesterol 250 mg/dl (&gt;&#xD;
             6.5mmol/L) or genetic hyperlipidaemia&#xD;
&#xD;
          -  Fasting triglycerides &gt; 400 mg/dL (4.5 mmol/L)&#xD;
&#xD;
          -  Known heterozygous or homozygous familial hypercholesterolaemia or know type III&#xD;
             hyperlipoproteinaemia (familial dysbetalipoproteinaemia)&#xD;
&#xD;
          -  ApoE2/E2 homozygosity, Apo E4/E4 homozygosity&#xD;
&#xD;
          -  Type 2 diabetes treated with oral agents and/or insulin&#xD;
&#xD;
          -  Diet treated type 2 diabetic patients with HbA1c ≥ 7%&#xD;
&#xD;
          -  History of cardio vascular disease&#xD;
&#xD;
          -  Systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 95 mmHg.&#xD;
&#xD;
          -  Very low-calorie diet (1200 calories a day or less) or history of surgical procedures&#xD;
             for weight loss (e.g., stomach stapling, bypass)&#xD;
&#xD;
          -  Body weight fluctuation &gt; 5 Kg during the previous 3 months&#xD;
&#xD;
          -  History of bulimia or anorexia nervosa by DSM-IV criteria&#xD;
&#xD;
          -  Presence of any clinically significant endocrine disease according to the&#xD;
             investigator, Cushing syndrome, obesity secondary to hypothalamic/pituitary disorder.&#xD;
&#xD;
          -  Abnormal TSH and free T4 at baseline (Patients treated with thyroid replacement&#xD;
             therapy must be on fixed and stable dose for at least 3 months prior to screening and&#xD;
             must be in euthyroïd status.)&#xD;
&#xD;
          -  Severe hepatic impairment known by the investigator or AST or ALT &gt; 3 times the ULN at&#xD;
             screening.&#xD;
&#xD;
          -  Known severe renal dysfunction (creatinine clearance &lt; 30 ml/min) or urine analysis&#xD;
             (performed at screening by dipstick) showing 2+ or more protein&#xD;
&#xD;
          -  Presence of any condition (medical, including clinically significant abnormal&#xD;
             laboratory test, psychological, social or geographical) actual or anticipated that the&#xD;
             investigator feels would compromise the patient safety or limit his/her successful&#xD;
             participation to the study&#xD;
&#xD;
          -  Patient treated for epilepsy&#xD;
&#xD;
          -  Ongoing major depressive illness&#xD;
&#xD;
          -  Uncontrolled psychiatric illness&#xD;
&#xD;
          -  History of alcohol and/or drug abuse&#xD;
&#xD;
          -  Smoker or smoking cessation within the past 3 months&#xD;
&#xD;
          -  Marijuana or hashish users&#xD;
&#xD;
          -  Previous participation in a Rimonabant study or to any other clinical trial within 4&#xD;
             weeks to study start&#xD;
&#xD;
          -  Hypersensitivity/intolerance to the active substance or to any of the excipients such&#xD;
             as lactose&#xD;
&#xD;
          -  Blood donation within the past 3 months prior to the study or planned during the study&#xD;
             or within the 3 months from the study completing&#xD;
&#xD;
          -  Recent history of active peptic ulcer&#xD;
&#xD;
          -  Willebrand disease or other hemorrhagic diatheses&#xD;
&#xD;
          -  Administration of any of the following within 3 months prior to screening visit and&#xD;
             susceptible to be prescribed during the study treatment period:&#xD;
&#xD;
          -  Lipid-lowering drugs intake&#xD;
&#xD;
          -  Anti obesity drugs&#xD;
&#xD;
          -  Other drugs for weight reduction (phentermine, amphetamines)&#xD;
&#xD;
          -  Herbal preparations for weight reduction&#xD;
&#xD;
          -  Other drugs known to affect lipid metabolism: retinoids, antiretroviral, estrogens and&#xD;
             hormone replacement therapy, cyclosporine, glitazones, benfluorex, fish oils, plant&#xD;
             sterols.&#xD;
&#xD;
          -  Thiazids (including fixed combination) at daily dose higher than 12.5 mg&#xD;
&#xD;
          -  Unselective beta-blockers&#xD;
&#xD;
          -  Prolonged use (more than one week) of systemic corticosteroids, neuroleptics&#xD;
&#xD;
          -  Anticoagulants&#xD;
&#xD;
          -  Ongoing antidepressive treatment&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Pilorget</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>North Ryde</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Finland</country>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <study_first_submitted>December 5, 2006</study_first_submitted>
  <study_first_submitted_qc>December 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2006</study_first_posted>
  <last_update_submitted>December 9, 2010</last_update_submitted>
  <last_update_submitted_qc>December 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Trial Transparency Team</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rimonabant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

